Verma Vivek, Simone Charles B, Zhen Weining
Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Oncologist. 2016 Feb;21(2):131-3. doi: 10.1634/theoncologist.2015-0348. Epub 2016 Jan 13.
Although the use of stereotactic ablative radiotherapy (SABR) for stage I small cell lung cancer is in its infancy, there are many reasons to believe that with more time and experience, it could emerge as the standard of care in inoperable patients, and perhaps even have equipoise with surgery for operable patients. Reporting of modeling studies and as much clinical data as possible are very much needed.
尽管立体定向消融放疗(SABR)用于I期小细胞肺癌尚处于起步阶段,但有很多理由相信,随着时间的推移和经验的积累,它可能会成为无法手术患者的标准治疗方法,甚至对于可手术患者可能与手术具有同等疗效。非常需要报告建模研究以及尽可能多的临床数据。